Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Alps Group Inc (Nasdaq: ALPS) reported fiscal year 2026 results ended March 31, 2026. Revenue rose 44% to $4.9 million, gross profit to $1.6 million, while net loss narrowed to $2.1 million. The company also said it completed a business combination with Globalink in Oct 2025 and began Nasdaq trading under ALPS, and updated its cellular therapy and diagnostics programs.
How this was made
The 30-second read
Why it matters
The release combines audited FY2026 financials with operational updates across cellular therapy (MyImmune), exosome pipeline expansion, and diagnostics/lab services (WGS accreditation) plus a PDO platform collaboration.
Market read
Traders may reassess the stock on revenue growth, margin compression, and progress toward manufacturing/validation and clinically oriented platform buildout, but without new clinical efficacy or guidance the catalyst is likely limited.
What to watch
The press release notes discontinuation of a COVID-19 mRNA vaccine candidate and reduced R&D spend, which could be interpreted as de-risking or as deprioritization without new late-stage clinical evidence.
Background
Alps Group Inc, an integrated biotech platform, transitioned to US public markets after completing a business combination with Globalink Investment Inc in October 2025 and listing on Nasdaq under ticker ALPS.
Ticker impact
Alps reports FY2026 results, with revenue up 44% to $4.9M and net loss $2.1M, plus pipeline and lab accreditation updates.
Likely modest, sentiment-driven move unless investors focus on pipeline milestones or margin trajectory.
The article provides concrete FY financials and several operational catalysts, but no guidance, cash balance, or clinical readout that would typically drive a large repricing.
Market effects
Adds incremental datapoints on small-cap biotech platform economics (commercial revenue supporting clinical pipeline) and genomics service expansion (WGS accreditation).
Highlights Southeast Asia clinical lab capability buildout (WGS under ISO 15189:2022) and Malaysia PDO platform development.
Limited global read-through given the company’s small revenue base and absence of major trial/approval milestones in the text.
Counterpoint
Revenue growth may be offset by margin compression (gross margin down to ~32%) and continued net losses, so the market may treat this as incremental rather than transformative.
Key entities
- companyAlps Group Inc
Nasdaq-listed integrated biotechnology platform reporting FY2026 results and business updates.
- companyGlobalink Investment Inc
Counterparty in the business combination completed in October 2025.
- subsidiaryMyGenome Sdn. Bhd.
Laboratory business expanding accreditation to include whole genome sequencing under ISO 15189:2022.
- programMyImmune
Natural killer cell therapy program progressing toward process validation.
